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Introduction {#sec001}
============

The maturation of mRNA 3′ ends is a 2-steps process, termed *cleavage and polyadenylation*, that involves endonucleolytic cleavage of the nascent RNA followed by synthesis of a poly(A) tail on the 3′ terminus of the cleaved product \[[@pgen.1008977.ref001]\]. Cleavage and polyadenylation sites (p(A) sites) are determined and controlled by adjacent RNA cis-regulatory elements, the principal among them is the *polyadenylation signal* (*PAS*) AAUAAA, typically located \~20-nt upstream of the p(A) site. There are more than 10 weaker variants to this canonical PAS, the main among them is AUUAAA \[[@pgen.1008977.ref002]\]. Auxiliary elements include upstream U-rich and UGUA motifs and downstream U-rich and GU-rich elements, and the strength of a p(A) site is determined by these elements in a combinatorial manner \[[@pgen.1008977.ref003]\]. Importantly, the majority of human protein-coding genes contain several alternative p(A) sites in their 3'UTR, making alternative polyadenylation (APA) a widespread regulatory layer that generates transcript isoforms with alternative 3′ ends, and correspondingly, different 3'UTR lengths \[[@pgen.1008977.ref001], [@pgen.1008977.ref004]--[@pgen.1008977.ref006]\]. As 3′ UTRs contain cis-elements that serve as major docking platforms for microRNAs (miRNAs) and RNA binding proteins (RBPs), which are involved in various aspects of mRNA metabolism, 3′ UTR APA can affect post-transcriptional regulation in multiple ways, including the modulation of mRNA stability, translation efficiency, nuclear export and cellular localization \[[@pgen.1008977.ref007]--[@pgen.1008977.ref009]\]. Transcriptomic studies demonstrated that APA is globally modulated during multiple differentiation processes \[[@pgen.1008977.ref004], [@pgen.1008977.ref010]--[@pgen.1008977.ref017]\] and in response to changes in cell proliferation state \[[@pgen.1008977.ref018]--[@pgen.1008977.ref020]\]. Yet, our current understanding of the impact of APA on gene regulation and of its biological roles is still very rudimentary.

Mutations in PAS and other poly(A) cis-elements, and the resulting alteration in gene expression have been shown to cause several human Mendelian diseases. Examples include the mutation in the 3'UTR of *HBA2* (converting AATAAA to AATAAG) causing α-Thalassaemia \[[@pgen.1008977.ref021]\], the mutation in the 3'UTR of *HBB* (AATAAA to AACAAA) causing β-Thalassaemia \[[@pgen.1008977.ref022]\] and the mutation in the 3'UTR of *FOXP3* (AATAAA to AATGAA) causing the IPEX syndrome \[[@pgen.1008977.ref023]\] (for a thorough review see \[[@pgen.1008977.ref024]\]). In addition, few common SNPs that regulate APA were found to affect the risk of complex diseases. This includes a risk SNP for systemic lupus erythematosus (SLE) located in the 3'UTR of *IRF5*. This SNP reduces the use of a proximal p(A) site, leading to the production of longer and less stable isoforms and consequently to reduced *IRF5* levels \[[@pgen.1008977.ref025]\]. Similarly, a polymorphic cis-element downstream to a PAS in the 3'UTR of *ATP1B1* is associated with high blood pressure \[[@pgen.1008977.ref026]\].

Given the high prevalence of APA, there are likely many more common SNPs that modulate APA and affect disease susceptibility. In this study, we systematically searched for SNPs that interfere with 3'UTR PAS signals in the human genome and implemented polyadenylation-QTL (pA-QTL) tests to examine their effect on APA. Analyzing GTEx RNA-seq data from twelve tissues we identified dozens of such SNPs that significantly affect the usage of their downstream p(A) sites. The intersection of these pA-QTLs with eQTLs and GWAS risk SNPs indicated their roles in the regulation of gene expression and their impact on various phenotypes.

Results {#sec002}
=======

pA-QTL analysis of PAS SNPs {#sec003}
---------------------------

We first sought to systematically identify SNPs in the human genome that affect 3'UTR APA. To focus our analysis on the ones likely to exert the strongest effect on gene regulation (and thus on phenotype), we specifically searched for SNPs that interrupt the canonical PAS (AATAAA) or its main variant (ATTAAA). Using p(A) sites annotations from polyA DB \[[@pgen.1008977.ref027]\], we overall detected 2,305 SNPs that interfere with these signals in a 40-nt window upstream of annotated 3'UTR p(A) sites in 1,936 unique genes ([Fig 1A](#pgen.1008977.g001){ref-type="fig"}; [S1 Table](#pgen.1008977.s007){ref-type="supplementary-material"}). We call such variants *PAS SNPs*. Each PAS SNP has one allele that preserves the PAS and another allele that interrupts it (called PAS Interrupting Allele (*PIA*)). Note that the PIA can be either the allele appearing on the genome reference sequence (the reference allele) or the alternative allele ([Fig 1B](#pgen.1008977.g001){ref-type="fig"}). 68% of the PAS SNPs were located within the canonical AATAAA PAS ([S1 Table](#pgen.1008977.s007){ref-type="supplementary-material"}). We associated each PAS SNP with its downstream p(A) site.

![Systematic identification of PAS SNPs in the human genome.\
**A**. We defined as *PAS SNPs* those that are located within 40-nt upstream of an annotated 3'UTR p(A) site and have an allele that interrupts the canonical PAS sequence AATAAA or its main variant ATTAAA. We considered all the 3'UTR p(A) sites annotated in poly(A) DB (release 3.2), and all \~37M SNPs included in GTEX v7. We detected 2,305 such SNPs. Each biallelic SNP has a reference allele (the allele that appears in the genome's reference sequence) and an alternative allele. Among the 2,305 PAS SNPs detected by our screen, 1,708 SNPs have the alternative allele interrupting the PAS sequence and 597 SNPs have the reference allele disrupting the signal. **B**. An example of a PAS SNP whose alternative allele interrupts the PAS signal (rs16858150 in the 3'UTR of *CACNA1E*; left) and a PAS SNP whose reference allele interrupts it (rs1866562 in the 3'UTR of *RNF169*; right).](pgen.1008977.g001){#pgen.1008977.g001}

PAS SNPs potentially have a strong impact on cleavage and polyadenylation efficiency at their downstream p(A) sites. To detect such effects we implemented pA-QTL tests that are based on the estimation of p(A)-site usage from RNA-seq data. Each PAS SNP divides its 3'UTR into two segments: a common UTR (cUTR) which is upstream to the associated p(A) site and is common to the transcript generated by cleavage at this p(A) site and the transcripts generated by usage of more distal p(A) sites, and an alternative UTR (aUTR) which is included only in transcripts generated by more distal p(A) sites ([Fig 2A](#pgen.1008977.g002){ref-type="fig"}). For each RNA-seq sample, we estimated the usage of each p(A) site associated with a PAS SNP by calculating the p(A) site Usage Index (*pAUI*), defined as the ratio (in log scale) between the number of reads mapped to the cUTR and the aUTR segments ([Fig 2A](#pgen.1008977.g002){ref-type="fig"}). Having RNA-seq data from a large cohort of individuals for which genotype data is available too, enables to test for association between the PAS SNP alleles and the pAUI levels ([Fig 2A](#pgen.1008977.g002){ref-type="fig"}). We carried out such pA-QTL tests on twelve selected tissues from the GTEx project (v7) \[[@pgen.1008977.ref028]\] that have more than 130 RNA-seq samples with corresponding genotype data ([Methods](#sec008){ref-type="sec"}; [S2 Table](#pgen.1008977.s008){ref-type="supplementary-material"}). Per tissue, and for each p(A) site linked with a PAS SNP, we examined variants within a window of +/- 10 kbp with respect to the p(A) site for association with pAUI levels using FastQTL \[[@pgen.1008977.ref029]\] ([Methods](#sec008){ref-type="sec"}). Overall, 512 pA sites were significantly associated (FDR ≤ 5%) with a pA-QTL in at least one tissue (see examples in [Fig 2B--2D](#pgen.1008977.g002){ref-type="fig"}; [S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}).

![pA-QTL analysis.\
**A**. We used the p(A) site usage index (pAUI) to quantify cleavage efficiency at each annotated 3'UTR pA site in each RNA-seq sample. The pAUI is defined as the ratio (in log2 scale) between the counts of 3'UTR reads mapped upstream of the pA site (common 3'UTR segment; cUTR) and those mapped downstream of it (alternative 3'UTR segment; aUTR) ([Methods](#sec008){ref-type="sec"}). We then used this index to detect PAS SNPs that show a significant association between alleles and pAUI levels of their p(A) site. SNPs showing such association are referred to as pA-QTLs. The expected pattern, as shown in this cartoon, is that the PAS-preserving allele is associated with higher usage of the p(A) site while the PAS-interrupting allele (*PIA*) is associated with reduced usage of this site (resulting in 3'UTR lengthening). Heterozygotes for such SNPs are expected to show intermediate pAUI levels compared to the two homozygotes. The cartoon illustrates reads coverage on a 3'UTR for three RNA-seq samples of varying levels of pAUI, colored according to the genotype of the PAS SNP. **B**--**D.** Examples of three PAS SNPs consistently detected as pA-QTLs in multiple tissues. In each example, the left panel shows read coverage in the gene's 3'UTR from RNA-seq samples of two selected donors from each PAS SNP genotype. The vertical purple line marks the location of the PAS SNP. The genome reference sequence around the PAS SNP is shown below. Violin plots in the middle and left panels show the distribution of pAUI levels in each genotype group for a given tissue (In each plot, homozygotes of the PAS-preserving allele are shown in the left, heterozygotes--in the middle, and homozygotes to the PAS-interrupting allele (PIA)--in the right violin. The number of individuals in each group is indicated in parentheses, shown are nominal p-values obtained using FastQTL linear regression as described in the Methods). (In C, "Brain" refers to "Brain caudal nucleus", and in D, "Heart AA" refers to "Heart atrial appendage").](pgen.1008977.g002){#pgen.1008977.g002}

Linkage disequilibrium (LD) patterns between adjacent genetic variants complicate the identification of causal variants. Therefore, next, we used CAVIAR \[[@pgen.1008977.ref030]\] to detect pA-QTL associations that can be more confidently ascribed to the effect of the corresponding PAS SNPs ([S1 Fig](#pgen.1008977.s001){ref-type="supplementary-material"}; [Methods](#sec008){ref-type="sec"}). Defining per pA site with a significant association a 95% credible set of variants, this analysis implicated the PAS SNP as a causal variant for 55%-70% of the observed pA-QTLs per tissue ([Fig 3A](#pgen.1008977.g003){ref-type="fig"}). Hereafter, we refer to PAS SNPs as PAS pA-QTLs if they (a) obtained in the pA-QTL tests p-values below their pA site-level thresholds (see [Methods](#sec008){ref-type="sec"}) and (b) were included in CAVIAR's credible sets. Overall, we detected 330 distinct PAS pA-QTLs, 70% of them interrupt a canonical PAS (and the rest interrupt the ATTAAA variant) ([S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}). Most of these PAS pA-QTLs were detected in multiple tissues ([Fig 3B](#pgen.1008977.g003){ref-type="fig"} and [S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}). The p(A) loci in which the PAS SNP was not included in CAVIAR's credible set indicate that there are additional mechanisms by which genetic variants affect APA other than disruption of PAS motifs ([S1C Fig](#pgen.1008977.s001){ref-type="supplementary-material"}).

![PAS SNPs indicated by CAVIAR as putative causal pA-QTLs.\
**A.** Bars showing the number of pA sites significantly associated with pA-QTLs per tissue, and the proportion of cases in which the corresponding PAS SNP is included in CAVIAR's credible set. **B.** Distribution of the number of different tissues in which each PAS SNP was indicated as pA-QTL variant. 49 PAS SNPs were indicated as causal pA-QTLs in at least 10 tissues.](pgen.1008977.g003){#pgen.1008977.g003}

As the PAS-interrupting allele (PIA) of PAS SNPs is expected to reduce cleavage efficiency at its p(A) site, we anticipated that the pA-QTL PIAs will be associated with lower pAUI (reflecting 3'UTR lengthening) ([Fig 2A](#pgen.1008977.g002){ref-type="fig"}). However, unexpectedly, we also identified PAS pA-QTLs whose PIA was associated with increased pAUI ([Fig 4A and 4B](#pgen.1008977.g004){ref-type="fig"}). Interestingly, in some of these cases, we observed that PIA's disruption of the cleavage at the corresponding p(A) site was associated with increased usage of an upstream (proximal) p(A) site (resulting in an increased pAUI and 3'UTR shortening). Yet, overall, the cases in which the PAI showed the expected 3'UTR lengthening effect were markedly more prevalent (84%-94%; [Fig 4C](#pgen.1008977.g004){ref-type="fig"}). Furthermore, remarkably, for PAS pA-QTLs that were detected in multiple tissues, the effect of their PIA on 3'UTR length was highly consistent across all tissues ([Fig 4D](#pgen.1008977.g004){ref-type="fig"}).

![The effect of PAS interrupting alleles (PIAs) on 3'UTR length.\
**A**. Cartoons illustrating the anticipated 3'UTR lengthening effect of PIAs (left) and the unexpected 3'UTR shortening effect, due to elevated usage of an alternative proximal p(A) site (right). Note that in the lengthening case the PIA is associated with decreased pAUI levels whereas in the shortening case, the PIA is associated with elevated pAUI levels. **B**. An example of a PAS pA-QTL (rs1130319 in the 3'UTR of *ADI1*) whose PIA is associated with 3'UTR shortening (increased pAUI). Notably, this PAS SNP is detected as a pA-QTL in five different tissues, and in all these cases its PIA is consistently associated with 3'UTR shortening effect (shown in **D**) (nominal p-values obtained using FastQTL linear regression as described in the Methods). **C**. A bar chart of the effect of PAS pA-QTL's PIAs on 3'UTR length per tissue. As expected, in the vast majority of cases the PIA showed a lengthening effect. **D.** PIA effect on 3'UTR length. Shown are all PAS pA-QTLs detected in at least five tissues. Remarkably, in all these cases, the PIAs showed a consistent effect over all the tissues in which its PAS SNP was detected as a pA-QTL.](pgen.1008977.g004){#pgen.1008977.g004}

Colocalization of PAS pA-QTL and eQTL signals {#sec004}
---------------------------------------------

APA can impact gene expression via regulation of transcript stability. Therefore, to test for possible functional effects of PAS SNPs on gene expression (e.g., through regulation of transcript stability), we examined overlaps between PAS pA-QTL signals detected by our analysis and eQTL signals identified by GTEx ([Fig 5A](#pgen.1008977.g005){ref-type="fig"}). Overall, of the 330 PAS pA-QTLs detected by our analysis, 133 overlapped an eQTL in at least one tissue. However, given the high abundance of eQTLs in the human genome, a simple intersection between PAS pA-QTLs and eQTLs might result in many false hypotheses on the causal effect of PAS SNPs on gene expression \[[@pgen.1008977.ref031]\]. Therefore, for loci in which a PAS pA-QTL intersected an eQTL, we used eCAVAIR \[[@pgen.1008977.ref032]\] to seek further support for these two signals tagging the same causal variant ([Methods](#sec008){ref-type="sec"}; [S2 Fig](#pgen.1008977.s002){ref-type="supplementary-material"}). Of the PAS pA-QTLs that overlapped an eQTL, 51 showed a high colocalization in at least one tissue ([S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}).

![Colocalization of pA-QTL and eQTL signals.\
**A**. An example of a PAS SNP (rs14434 in the 3'UTR of *EIF2A*) that is both a pA-QTL and an eQTL (of this gene). The PIA of rs14434 (which is the C allele) is associated with lower pAUI at the corresponding p(A) site (and thus, 3'UTR lengthening) and lower expression level of *EIF2A*. Notably, rs14434 consistently showed this same effect in five different tissues (**Fig 5D**). **B.** An example of the uncommon case where a PIA (the G allele, in this case) was associated with decreased pAUI of the corresponding p(A) site (that is, 3'UTR lengthening) but with higher expression of the target gene. This PIA showed the same effect in three different tissues (**Fig 5D**) (pA-QTL nominal p-values calculated using FastQTL linear regression as described in the Methods, eQTL p-values were obtained from GTEx v7). **C**. A Cleveland dot plot of the PAS pA-QTLs overlapping an eQTL (for the same gene) whose PIA showed a 3'UTR lengthening effect. Arrow indicates the direction of the link between the PIA and gene expression. In all tissues, 3'UTR lengthening was significantly associated with decreased expression (one-tailed binomial tests, p-values \< 0.05 in all tissues). **D.** Association between PIA effect on 3'UTR length (coded by color) and gene expression (shown by an arrow). Cases supported by the colocalization of the pA-QTL and eQTL signals (CLPP \> 0.01) are shown in darker colors. (Shown in this heatmap are the PAS pA-QTLs with lengthening/shortening effect in at least seven tissues and that overlapped a GTEx eQTL in at least one tissue. Squares with no color indicate no overlap with eQTL).](pgen.1008977.g005){#pgen.1008977.g005}

Next, we examined a possible association between the effect of PIAs on 3'UTR length (lengthening or shortening) and gene expression (increased or decreased expression). As 3'UTR cis-regulatory elements mostly have destabilizing effects (e.g., ARE elements, microRNA binding sites), we expected that PIAs associated with 3'UTR lengthening will consequently be mainly associated with decreased expression level ([Fig 5A](#pgen.1008977.g005){ref-type="fig"}). Yet, we detected few uncommon cases in which 3'UTR lengthening effect of a PIA was associated with increased gene expression level (see [Fig 5B](#pgen.1008977.g005){ref-type="fig"} for one example). Yet overall, in line with our expectations, in all tissues 3'UTR lengthening was significantly associated with decreased expression than with increased one ([Fig 5C](#pgen.1008977.g005){ref-type="fig"}). Notably, both patterns of association with expression level were highly consistent across different tissues ([Fig 5D](#pgen.1008977.g005){ref-type="fig"}). For example, the PIA of the PAS SNP in the 3'UTR of *UTP4* showed significant association with 3'UTR lengthening and decreased expression level in all twelve tissues, and the PIA of the PAS SNP in the 3'UTR of *PPP2R1B* showed a consistent association with 3'UTR lengthening and increased expression levels in six different tissues ([Fig 5D](#pgen.1008977.g005){ref-type="fig"}). PIAs linked with 3'UTR shortening were not prevalent enough to allow robust statistical testing of their association with increased or decreased expression ([Fig 5D](#pgen.1008977.g005){ref-type="fig"}).

Colocalization of PAS pA-QTL and GWAS signals {#sec005}
---------------------------------------------

Next, we sought possible links between the PAS pA-QTLs we identified and human phenotypes by intersecting these variants with GWAS risk SNPs ([Methods](#sec008){ref-type="sec"}). We analyzed GWAS summary statistics from 124 studies ([S4 Table](#pgen.1008977.s010){ref-type="supplementary-material"}). In total, 104 PAS pA-QTLs overlapped at least one GWAS SNP (70 of which had GWAS lead SNP with p-value \< 5e-8 and the rest had 5e-8 ≤ p-value \< 1e-5), in 237 (158 when considering only GWAS lead SNP with p-value \< 5e-8) PAS pA-QTL-GWAS SNP pairs. However, similar to eQTLs, given the high abundance of GWAS SNPs, pA-QTLs and GWAS SNPs can simply co-occur by chance \[[@pgen.1008977.ref031]\]. Therefore, here too, we applied eCAVIAR to gain higher confidence for the potential causal effect of the PAS pA-QTLs on the complex traits. Overall, 78 (40) PAS pA-QTL and GWAS signals (from 37 (18) distinct PAS pA-QTLs) showed marked colocalization ([S3 Fig](#pgen.1008977.s009){ref-type="supplementary-material"} and [S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}). Nine (six) of these PAS pA-QTLs in nine (six) distinct genes were also colocalized with eQTL signals, suggesting novel links between APA and phenotype which are mediated through modulation of gene expression. These cases included the PAS pA-QTL in the 3'UTR of *BECN1*, a key regulator of autophagy. This pA-QTL was colocalized both with eQTL signals for *BECN1* and GWAS signals for type 2 diabetes ([Fig 6A](#pgen.1008977.g006){ref-type="fig"}). Notably, autophagy abnormality has been recently associated with metabolic disorders, such as type 2 diabetes, and the BECN1 protein was shown to regulate insulin secretion. It was demonstrated that, in insulin-producing ß cells, excess autophagy degrades insulin-containing vesicles, resulting in decreased insulin contents and systemic glucose intolerance; whereas in insulin-responsive cells, activating autophagy decreases endoplasmic reticulum (ER) stress and improves insulin sensitivity \[[@pgen.1008977.ref033]\]. Interestingly, the PIA of this PAS SNP is associated with 3'UTR lengthening, decreased *BECN1* expression and decreased T2D risk ([S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"}). Other examples are the PAS pA-QTL in the 3'UTR of *PPP2R1B* that is colocalized with an eQTL for this gene and with GWAS signal of body fat distribution ([Fig 6B](#pgen.1008977.g006){ref-type="fig"}; interestingly, *PPP2R1B* shows outstanding high expression in fat pad tissues (Entrez Gene page)); and the PAS pA-QTL in the 3'UTR of *DIP2B* that is colocalized with an eQTL for this gene and with GWAS signal of red blood cell width ([Fig 6C](#pgen.1008977.g006){ref-type="fig"}). Of note, our analysis did not capture the known association between the PAS SNP in the 3'UTR of IRF5 and risk for SLE \[[@pgen.1008977.ref025]\], because this locus likely contains several causal variants that act through different mechanisms, some of which have a stronger effect on IRF5 expression and SLE risk than the PAS pA-QTL ([S4 Fig](#pgen.1008977.s004){ref-type="supplementary-material"}). Accordingly, this PAS pA-QTL showed colocalization with the GWAS signal only after increasing eCAVIAR's setting for the number of putative causal variants in this locus to five (and with the eQTL signal after increasing the number of putative causal variants to three) ([S5 Table](#pgen.1008977.s011){ref-type="supplementary-material"}).

![Colocalization of pA-QTL, eQTL and GWAS signals.\
Examples of PAS pA-QTLs that showed marked colocalization with both eQTL and GWAS signals in the 3'UTRs of the genes: **A**. *BECN1*. **B**. *PPP2R1B*. **C**. *DIP2B*. Dots are colored according to their LD (r^2^**)** with the PAS SNP (calculated according to GTEx VCF files for eQTL plots and according to genome 1000 VCFs files for GWAS plots). Diamond shape signifies the PAS SNP. CLPP is colocalization posterior probability calculated using eCaviar ([Methods](#sec008){ref-type="sec"}).](pgen.1008977.g006){#pgen.1008977.g006}

pA-QTL analysis of 3'UTR SNPs {#sec006}
-----------------------------

The above analyses were focused on SNPs that interrupt the canonical PAS signals, as those are expected to exert the strongest effect on APA. Yet, APA is regulated by additional 3'UTR cis-elements, including upstream U-rich and UGUA motifs, downstream U-rich and GU-rich elements and multiple RNA-binding sites \[[@pgen.1008977.ref001]\]. Genetic variants that interfere with such auxiliary elements are expected too to modulate cleavage efficiency at their respective p(A) sites, albeit with weaker impact. Therefore, last, we extended our analysis and searched for 3'UTR SNPs that are associated with APA modulation without disrupting PAS elements. The pAUI, which is based on pA site annotations, allows a high-resolution quantification of the usage of its PAS pA site. To analyze the effect of other variants on APA and consequently on 3'UTR length, we turned to using the distal p(A) site usage indexes provided by the APA Atlas \[[@pgen.1008977.ref034]\] ([Methods](#sec008){ref-type="sec"}), as indexes for the overall (relative) 3'UTR length in each RNA-seq sample. This genome-wide 3'UTR pA-QTL analysis (covering 25,293 3'UTRs from 22,903 genes) identified 27,994 pA-QTLs in 3,653 3'UTRs (3,501 genes) (and after excluding 3'UTRs containing PAS SNPs, 26,197 pA-QTLs in 3,577 3'UTRs of 3,429 genes). As anticipated, these pA-QTLs showed weaker effect sizes than the PAS pA-QTLs ([Fig 7A](#pgen.1008977.g007){ref-type="fig"}). These additional pA-QTLs may modulate APA via multiple, direct and indirect, mechanisms. To further characterize one potential mechanism, we found 41 pA-QTLs (in 40 genes), supported by CAVIAR as likely tagging causal variants, that interfered with the GUGU motif, located within 20 nt downstream of their respective p(A) sites ([Fig 7B](#pgen.1008977.g007){ref-type="fig"}; [S6 Table](#pgen.1008977.s012){ref-type="supplementary-material"}). The effect sizes of these GUGU pA-QTLs were too markedly lower than those of the PAS pA-QTLs ([S5 Fig](#pgen.1008977.s005){ref-type="supplementary-material"}). Unlike the sharp tendency for 3'UTR lengthening effect exerted by the PAS pA-QTLs ([Fig 4C](#pgen.1008977.g004){ref-type="fig"}), as a set the GUGU-interfering pA-QTLs did not generally show a clear directional effect on 3'UTR length ([Fig 7C](#pgen.1008977.g007){ref-type="fig"}). Yet, individually they showed a consistent effect across different tissues ([Fig 7D](#pgen.1008977.g007){ref-type="fig"}). For example, the pA-QTL disrupting the GUGU motif in the 3'UTR of *TXN* was associated with 3'UTR lengthening in all twelve tissues ([Fig 7D](#pgen.1008977.g007){ref-type="fig"}). Colocalization analysis of pA-QTL and eQTL signals supported some of these GUGU-interfering SNPs as variants underlying both associations ([Fig 7D](#pgen.1008977.g007){ref-type="fig"}; [S6 Table](#pgen.1008977.s012){ref-type="supplementary-material"}).

![Genome-wide pA-QTL analysis of 3'UTR SNPs.\
**A**. Comparison between effect magnitudes (the absolute value of the slope calculated by FastQTL) of PAS pA-QTLs and other 3'UTR pA-QTLs (for both sets, we did not require here inclusion in CAVIAR's credible set). **B**. Location distribution of the GUGU motif with respect to 3'UTR p(A) sites (annotated in polyA DB). This motif shows a strong peak at \~20 nt downstream of the cleavage site. **C**. The effect of pA-QTLs interrupting a GUGU motif on 3'UTR length. (This analysis included the subset of these variants that were contained in CAVIAR's credible set; \*p-value\<0.05; calculated using a one-tailed binomial test). **D.** Association between pA-QTLs interrupting a GUGU motif, 3'UTR length and gene expression (eQTLs). Shown here are variants detected as pA-QTLs in at least three tissues. Colors are as in [Fig 5D](#pgen.1008977.g005){ref-type="fig"}.](pgen.1008977.g007){#pgen.1008977.g007}

Discussion {#sec007}
==========

Despite the emergence of APA as an important layer of gene regulation, potentially affecting the majority of human protein-coding genes, it remains largely unexplored, and its involvement in physiological and pathological processes is often overlooked. Here, we searched for SNPs that modulate APA. Focusing on SNPs likely to have the strongest effect, we identified 2,305 SNPs that interfere with the canonical PAS or its main variant. Seeking support for the regulatory impact of these SNPs on APA, we implemented pA-QTL tests using GTEx RNA-seq data from twelve tissues. Our analysis detected 330 PAS pA-QTLs with a significant effect in at least one tissue, which was supported by CAVIAR's fine-mapping as tagging causal variants. As expected, for the vast majority of these pA-QTLs, the PAS-interrupting allele caused decreased cleavage at its p(A) site that resulted in 3'UTR lengthening ([Fig 4C](#pgen.1008977.g004){ref-type="fig"}). Yet, interestingly, in \~10% of the cases, the effect of the PAS-interrupting allele was associated with 3'UTR shortening, due to elevated usage of a more proximal p(A) site ([Fig 4A and 4B](#pgen.1008977.g004){ref-type="fig"}). This observation argues against a scanning mechanism as the mode of action of the polyadenylation machinery. The fact that reduced efficiency of a p(A) site augments cleavage and polyadenylation at an upstream p(A) site implies a thermodynamic competition between the alternative p(A) sites.

Our tests for the identification of PAS pA-QTLs were applied to each tissue separately. Yet, many of these variants showed a consistent effect across different tissues. Modern statistical methods strive to increase power by sharing information across conditions. Indeed, applying MASH, a recently developed method for joint multivariable analyses \[[@pgen.1008977.ref035]\], to the set of PAS SNPs markedly increased the number of PAS SNPs detected as pA-QTLs across multiple tissues ([S6A and S6C Fig](#pgen.1008977.s006){ref-type="supplementary-material"}). Nevertheless, attention should be paid not only to statistical significance but also to effect sizes. Notably, the PAS SNPs which, in the MASH analysis, had a significant effect on APA in all twelve tissues, showed high heterogeneity in the magnitude of their effect over the tissues ([S6B Fig](#pgen.1008977.s006){ref-type="supplementary-material"}), similar to results recently observed for eQTLs \[[@pgen.1008977.ref035]\].

APA potentially affects post-transcriptional gene regulation in multiple ways, including modulation of mRNA stability, translation efficiency, nuclear export, and cellular localization. However, two recent studies failed to detect a large effect of APA on transcript stability or translation efficiency \[[@pgen.1008977.ref036], [@pgen.1008977.ref037]\]. We sought an indication of the functional impact of the PAS SNPs on gene expression. To this goal, we intersected the PAS pA-QTLs identified by our analysis with GTEx eQTLs and found that 133 of them, in at least one tissue, were also detected as eQTLs of the same gene. Noting that given the high abundance of eQTLs in the human genome, such overlaps are likely to occur by chance, we further used eCAVIAR to examine colocalization of the pA-QTL and eQTL signals. This analysis indicated 51 PAS SNPs as underlying causal variants for the association with both APA and gene expression. As cis-regulatory elements embedded within 3'UTRs mainly carry destabilizing roles (e.g., miRNA binding sites, AU-rich elements (AREs)) \[[@pgen.1008977.ref038]\], we expected that 3'UTR lengthening effects of the PAS-interrupting alleles will be mostly linked with reduced gene expression. We indeed observed such link in all twelve tissue ([Fig 5C](#pgen.1008977.g005){ref-type="fig"}). These results indicate the regulatory impact of APA on gene expression, where shorter isoforms generated by APA are generally more stable than longer ones. Nevertheless, the impact of 3'UTR APA on transcript stability is more complicated than mere inclusion/exclusion of regulatory elements in/from the 3'UTR, since the efficiency of mRNA targeting by such elements can be also affected by their location, as was demonstrated for miRNA target sites: sites located at the start or end of the 3'UTRs are more efficient than those located in the middle \[[@pgen.1008977.ref039]\]. Thus, APA can modulate the activity of miRNA target sites by changing their location relative to the transcript's 3' end \[[@pgen.1008977.ref040]\].

Over the last decade, GWAS studies discovered thousands of SNPs associated with common diseases and traits (The GWAS catalog already reports \>70k tag SNPs \[[@pgen.1008977.ref041]\]). Yet, the mechanism of action of most of the genetic variants identified by GWAS is currently unknown. Functional interpretation is hindered by the fact that the vast majority (\>90%) of these SNPs map to noncoding regions of the genome \[[@pgen.1008977.ref042]\]. While disruption of enhancer elements regulating gene transcription emerges as the main mode of action of risk SNPs \[[@pgen.1008977.ref042]\], marked fractions of traits' heritability are not accounted for by SNPs that map to transcriptional regulatory elements (e.g., putative enhancers and promoters) \[[@pgen.1008977.ref043]\]. This indicates that other modes of action mediate the impact of noncoding genetic variants on human traits. Modulation of APA can be an important additional mechanism, and in this study, we identified 104 PAS pA-QTLs that overlapped GWAS SNPs (in 237 pA-QTL-GWAS trait pairs). However, similar to eQTLs, GWAS SNPs are too highly abundant in the human genome, and thus such overlaps may occur just by chance. To gain higher confidence in the potential causal effect of the PAS pA-QTLs on the complex human traits, we applied eCAVIAR, and detected marked colocalization of the pA-QTL and GWAS signals for 78 pairs in 37 distinct 3'UTR loci. Our analysis mainly focused on PAS SNPs as they are expected to have the strongest impact on APA (and consequently, on gene expression and human traits). Nevertheless, our extended, analysis of 3'UTR pA-QTLs suggests that thousands of additional variants effect (although with weaker magnitude) gene expression and human phenotypes by APA modulation. Very recently, Yang et al. \[[@pgen.1008977.ref044]\] carried out a similar pA-QTL analysis on 32 human cancer types using RNA-seq data from The Cancer Genome Atlas (TCGA) and their study too detected thousands of cis pA-QTLs.

Given the critical roles potentially played by APA in gene regulation and our limited understanding of how it is affected by genetic variants, our methodology and findings contribute to the initial elucidation of associations between PAS SNPs, gene expression and human phenotypes.

Methods {#sec008}
=======

Identification of PAS SNPs {#sec009}
--------------------------

To identify PAS SNPs, we started with all 106,571 p(A) sites located in 3'UTRs from poly(A) DB (release 3.2) \[[@pgen.1008977.ref027]\], and all 37,611,962 annotated SNPs from GTEX v7 \[[@pgen.1008977.ref028]\]. We considered the 53,428 SNPs located within 40-nt upstream of an annotated 3'UTR p(A) site. Examining the sequences spanning 5-nt upstream and 5-nt downstream of these SNP, we identified 2,260 instances in which one of the alleles (reference or alternative) constitute a canonic PAS sequence (AATAAA) or its main variant (ATTAAA), while the other allele interrupts this signal (we call this allele the PAS-interrupting allele---*PIA*). We also detected 45 instances in which one allele constitutes the canonic PAS, while the other allele constitutes the main variant.

GTEx data {#sec010}
---------

Aligned GTEx paired-end RNA-seq were obtained from dbGaP (release phs000424.v7.p2). We used SAMtools \[[@pgen.1008977.ref045]\] and SRA tools to convert cram and SRA files, respectively, to BAM format. We used RNA-seq data from 12 tissues that have more than 130 RNA-seq samples with corresponding genotype data ([S2 Table](#pgen.1008977.s008){ref-type="supplementary-material"}). SNP genotypes were obtained from GTEx v7 VCF file, which is based on whole-genome sequencing (we used VCF processed files from which low-quality sites and samples are filtered out by GTEx).

pA-QTL analysis of PAS SNPs {#sec011}
---------------------------

We associated each PAS SNP with its p(A) site (located within 40-nt downstream of it; if a PAS SNP had more than one annotated p(A) site within downstream 40-nt, the nearest p(A) site was taken). We split the 3'UTRs containing a PAS SNP into two segments: the common 3'UTR (*cUTR*; the segment upstream of the p(A) site) and the alternative 3'UTR (*aUTR*; the 3'UTR segment downstream of the p(A) site). 3'UTR coordinates were downloaded from the UCSC genome browser based on GENCODE hg19 release v31 \[[@pgen.1008977.ref046]\]. Overlapping 3'UTRs of the same gene were merged using bedtools \[[@pgen.1008977.ref047]\]. When the p(A) site of a PAS SNP was located at the edge of the 3'UTR, the entire 3'UTR was considered as the cUTR and the downstream 1,000 nt were considered as the aUTR.

We defined the pA site Usage Index (*pAUI*) to quantify the usage of each p(A) site associated with a PAS SNP in each RNA-seq sample: $$pAUI = {\text{log}_{2}{\left( \frac{cUTR\mspace{720mu} counts + 1}{aUTR\mspace{720mu} counts + 1} \right),}}$$ where *cUTR counts* is the fragment counts in the cUTR, and *aUTR counts* is the fragment counts in the aUTR. A pseudo count of 1 was added to avoid zeroes.

We used featureCounts \[[@pgen.1008977.ref048]\] with a SAF file containing the coordinates of the 3'UTR segments to count the number of reads mapping to aUTRs and cUTRs in each sample. Sequenced fragments that overlapped a 3'UTR were considered in the following way: if at least one of the fragment's reads intersected the aUTR region, the fragment was assigned to the aUTR; otherwise, the fragment was assigned to the cUTR segment. Only reads that were uniquely mapped (mapping quality of 255), aligned in proper pairs, and not marked as PCR duplicates, were counted.

We next used the pAUI levels for a pA-QTL analysis. We carried out this analysis for each tissue separately. To ensure sufficient statistical power while lowering the burden of multiple testing, for each tissue, we included in our analysis only 3'UTRs with a median RPKM ≥ 1 across samples and corresponded to genes that were included in GTEx v7 analysis (namely genes with \> 0.1 TPM and ≥ 6 reads in 20% of the samples). We performed the pA-QTL analysis using FastQTL \[[@pgen.1008977.ref029]\]. We added sequencing platform (Illumina HiSeq 2000 or HiSeq X), sex, the top three genotype principal components and PEER factors (obtained from the GTEx data portal) as covariates. For each tissue and each 3'UTR containing a PAS SNP, we examined all variants located within 10 kbp of the corresponding pA site whose minor allele frequencies ≥0.01 and with the minor allele observed in at least 10 samples. To account for testing multiple (correlated) variants within each pA site window, we followed the procedure applied by GTEx v7 \[[@pgen.1008977.ref028]\]. Briefly, we ran FastQTL with the permutation mode to obtain empirical p-values extrapolated from a Beta distribution (FastQTL setting--permute 1000 10000). This mode reports the p-value of the most significant variant in a locus (pA site, in our analysis). These p-values were further corrected for multiple testing (due to testing pA sites over multiple 3'UTRs) using Storey's q-value method \[[@pgen.1008977.ref049]\]. pA sites with q-value \< 0.05 were considered significantly associated with a pA-QTL.

For each significant pA locus, we applied CAVIAR \[[@pgen.1008977.ref030]\] to define the 95% credible set, which contains the causal variant with high confidence. The inputs to CAVIAR for each set were variants' t-statistics (calculated from the slope and slope standard error from FastQTL) and their pairwise LD (*r*) calculated using PLINK 1.9 (---r square). (PLINK's binary file was created from GTEx VCF using plink---make-bed and specifying---keep allele-order). Since we suspect that in each tested pA locus the PAS SNP is the causal variant, CAVIAR was run with one causal variant mode (-c 1) and otherwise default parameters. We considered a PAS SNP as a likely causal pA-QTL (referred to as a PAS pA-QTL) if (a) it was included in the credible set of its pA locus and (b) its nominal p-value was below its pA-locus threshold calculated following GTEx's procedure for obtaining a gene-level nominal p-value threshold based on its beta distribution model \[[@pgen.1008977.ref028]\].

All tests were performed in R-3.5.1 and plots were made using ggplot2 R package.

Colocalization of pA-QTL and eQTL signals {#sec012}
-----------------------------------------

For each tissue, we first intersected its GTEx v7 list of significant eQTLs (significant variant-gene pairs obtained from GTEx .signif_variant_gene_pairs.txt files) with its list of PAS pA-QTLs (requiring that these eQTLs are linked to the genes in which they are located). We then used eCAVIAR \[[@pgen.1008977.ref032]\] to test these cases for colocalization of the eQTL and pA-QTL signals. (The strength of colocalization between two genomic signals is measured by eCAVAIR's colocalization posterior probability (CLPP)). For each pair of a PAS pA-QTL and its overlapping eQTL, eCAVIAR analysis included variants located within +/- 10 kbps with respect to the corresponding pA site (filtered as described above for the pA-QTL analysis). eCAVIAR input per p(A) locus were the variants' t-statistics obtained by the pA-QTL and eQTL tests and pairwise LD scores calculated as described above for CAVIAR analysis. eCAVIAR was run using the 1 causal variant mode (-c 1), and otherwise, default parameters. We followed eCAVIAR authors' practice and considered CLPP \> 0.01 as an indication for colocalization.

Colocalization of pA-QTL and GWAS signals {#sec013}
-----------------------------------------

We used summary statistics from 124 GWAS studies ([S4 Table](#pgen.1008977.s010){ref-type="supplementary-material"}) to find overlaps between PAS pA-QTLs and significant GWAS SNPs (p-value for a given trait \< 1e-5, we also distinguish in [S3 Table](#pgen.1008977.s009){ref-type="supplementary-material"} cases for which the lead GWAS SNP in the locus had p-value \< 5e-8). Similar to the analysis of colocalization between pA-QTLs and eQTLs, here too we used eCAVIAR to seek further support for the pA-QTLs and GWAS SNPs tagging the same causal variants. For each such overlap, the input to eCAVIAR was the pA-QTL's t-statistics and GWAS' z-scores of variants included in both datasets and that are located within +/- 10 kbp of the respective pA site, and LDs for GTEx and GWAS calculated from GTEx VCF file and 1000 genome VCF files respectively.

As eCAVIAR requires the direction of effect and direction of LD, we aligned the GWAS z-scores such that the reference allele (non-effect allele) is the same as the GTEx reference allele. Furthermore, to align the pA-QTL eQTL LDs, we used BCF tools \[[@pgen.1008977.ref050]\] to match the reference alleles of the genome 1000 VCFs to those of GTEx (After using BCF tools to split multiallelic sites to biallelic). We then used PLINK specifying -keep allele-order when creating PLINK binary files (this step is required as by default, PLINK 1.9 uses the major allele as the reference). eCAVIAR was run using the 1 causal variant mode (-c 1), and otherwise, default parameters.

Genome-wide pA-QTL analysis of 3'UTR SNPs {#sec014}
-----------------------------------------

In this analysis, we used the distal p(A) site usage index provided by the APA-Atlas \[[@pgen.1008977.ref034]\], calculated per transcript in each GTEx sample (transcripts with less than 30 reads in their last exon were removed by APA-atlas). We included in this analysis all variants located within 3'UTRs or their 2.5 kbp flanking regions (GENCODE hg19 release v31) whose minor allele frequencies ≥0.01 and with the minor allele observed in at least 10 samples. To identify pA-QTLs, each 3'UTR interval was analyzed by FastQTL, using the same procedure and the same covariates described above for the analysis of PAS SNPs. Variants (a) located in 3'UTR loci with q-value\<0.05 and (b) obtained nominal p-value below the interval-specific threshold were considered significant 3'UTR pA-QTLs. CAVIAR and eCAVIAR analyses were applied to the significant variants that interrupt GUGU element as described above for the PAS pA-QTLs.

MASH {#sec015}
----

We used MASH (multivariate adaptive shrinkage) \[[@pgen.1008977.ref035]\] as implemented by mashr. Analyzing 3'UTRs with PAS SNPs, the inputs were the matrix of effect estimates and the matrix of corresponding standard errors (slope and slope standard error calculated by FastQTL) of the set of 26,140 variants that passed the variants' filtering criteria (see above) in all tissue. We fitted the MASH model using both data-driven and canonical covariance as recommended by the authors. To obtain the data-driven covariance, we used mashr built-in functions (*get_significant_results*, *cov_pca*). In this analysis we considered a PAS SNP as a pA-QTL PAS if (a) its local false sign rate (*lsfr*) was below 0.05, and (b) it was included in CAVIAR's credible set. CAVIAR was run as described above, with FastQTL t-statistics replaced by the ratio of the posterior mean and posterior standard error obtained from MASH.

Raw data for the figures and supplemental tables of this study are available at <https://github.com/ElkonLab/pA_QTLs>.

Supporting information {#sec016}
======================

###### CAVIAR fine-mapping analysis.

**A**. The credible sets that were defined by CAVIAR for the pA loci presented in [Fig 2B--2D](#pgen.1008977.g002){ref-type="fig"}. **B**. Examples for PAS SNPs with very high posterior probability pointing them as the causal pA-QTL variants with very high confidence. **C**. Examples of PAS SNPs that obtained a significant p-value in the pA-QTL tests, but were not included in the credible sets of their pA loci, indicating that they are not the causal ones. Varaints included in the credible set are colored in green. Otherwise, the legend is as in [Fig 6](#pgen.1008977.g006){ref-type="fig"}.

(TIF)

###### 

Click here for additional data file.

###### eCAVIAR colocalization analysis of pA-QTL and eQTL signals.

**A**. Examples of loci showing strong colocalization of the pA-QTL and eQTL signals (very high colocalization posterior probability (CLPP)), indicating the PAS SNP as the causal variant for both effects. **B**. Examples of weak colocalization of the pA-QTL and eQTL signals (low CLPP), suggesting that the eQTL tags a causal variant that is distinct from the PAS SNP. **C**. Strong colocalization of the pA-QTL and eQTL signals in the loci shown in [Fig 5A and 5B](#pgen.1008977.g005){ref-type="fig"}. Legend is as in [Fig 6](#pgen.1008977.g006){ref-type="fig"}.

(TIF)

###### 

Click here for additional data file.

###### eCAVIAR colocalization analysis of pA-QTL and GWAS signals.

Examples of PAS pA-QTLs and GWAS SNPs showing high colocalization (CLPP\>0.01), indicating a common underlying causal mechanism. Legend is as in [Fig 6](#pgen.1008977.g006){ref-type="fig"}.

(TIF)

###### 

Click here for additional data file.

###### Relationship between pA-QTL, eQTL and SLE GWAS signals in the 3'UTR locus of *IRF5*.

Legend is as in [Fig 6](#pgen.1008977.g006){ref-type="fig"}, See [S6 Table](#pgen.1008977.s012){ref-type="supplementary-material"}.

(TIF)

###### 

Click here for additional data file.

###### Comparison between effect magnitudes of PAS pA-QTLs, GUGU pA-QTL and other 3'UTR pA-QTLs.

Axis and legend as [Fig 7A](#pgen.1008977.g007){ref-type="fig"}.

(TIF)

###### 

Click here for additional data file.

###### MASH information sharing across conditions increases statistical power for the detection of pA-QTL effects.

**A**. Distribution of the number of different tissues in which each PAS SNP pA-QTL was detected by the tissue-by-tissue tests (left) and by MASH analysis utilizing information sharing across tissues (the analysis shown here includes variants that were tested (that is, passed the filtering criteria) in all tissues). The proportion of PAS SNPs that were detected as pA-QTLs in at least nine tissues was up from 20% in the tissue-by-tissue tests to 45% in MASH analysis. **B.** PAS SNPs with a significant effect in all twelve tissues (39 SNPs) show high variation in their effect sizes over the tissues. For each PAS SNP detected by MASH as a pA-QTL in all tissues, we calculate the ratio between its maximal and minimal effect size (MASH posterior mean). The violin plot shows the distribution of these ratios. A third of these pA QTLs show more than a 2-fold difference in their effect size. **C**. An example of a PAS pA-QTL that reached statistical significance in only two tissues (Thyroid and Blood) by the tissue-by-tissue FastQTL tests, and turned significant in ten tissues by MASH analysis based on information sharing across tissues. (The indicated p-values are those obtained by the tissue-by-tissue FastQTL tests, asterisks next to the tissue name indicate pA-QTL according to MASH analysis).

(TIF)

###### 

Click here for additional data file.

###### 3'UTR SNPs interrupting a canonical PAS (AATAAA) or its main variant (ATTAAA).

(XLSX)

###### 

Click here for additional data file.

###### GTEx tissues analyzed in our study.

(XLSX)

###### 

Click here for additional data file.

###### PAS pA-QTLs and their association with eQTLs and GWAS SNPs.

(XLSX)

###### 

Click here for additional data file.

###### GWAS summary statistics datasets analyzed in our study.

(XLSX)

###### 

Click here for additional data file.

###### SLE IRF5 eCaviar analysis results.

(XLSX)

###### 

Click here for additional data file.

###### GUGU-interfering variants and their association with eQTLs.

(XLSX)

###### 

Click here for additional data file.
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Dear Dr Elkon,

Thank you very much for submitting your Research Article entitled \'Systematic identification of functional SNPs interrupting 3\' UTR polyadenylation signals\' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and by two independent peer reviewers. As you will see, the reviewers (and the editors) believe that this work addresses a timely question which appears to be of high interest to the broad genetics community and has to great potential to significantly advance the field. However, one of the reviewers has raised major points that need to be addressed before the manuscript can be considered for publication.  Based on the reviews and our editorial evaluation, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.
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Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The manuscript "Systematic identification of functional SNPs interrupting 3' UTR polyadenylation signals" by Shulman and Elkon examines genome-wide, the effect of SNPs that interrupt the polyadenylation signal (PAS) in the 3' UTR on differential poly(A) site usage using RNA-seq data from 12 tissues in GTEx through QTL analysis (pA-QTL) and their relationship with complex disease or trait associations. The authors focus on variants that fall in canonical PAS within 40 nucleotides of the poly(A) tail, which are expected to have the strongest effects on polyA. They find 139 significant pA-QTLs, half of which overlap with expression QTLs (eQTLs), and 53 of which are in linkage disequilibrium (LD) with complex disease or trait associations, proposing a new (under investigated) molecular mechanism that may underlie genetic associations with complex diseases/traits. One finding the authors find unexpected is that 12% of variants in the polyA motif that lead to 3' UTR lengthening are associated with increased expression of the gene, while 88% of cases are associated with decrease in expression. Transcript lengthening has primarily been thought to have a destabilizing effect.

This work presents afirst systematic, genome-wide examination of variants in PAS association with differential polyadenylation levels in various tissues, providing new insights on the effect of genetic variation on transcript expression and human complex traits. While I think such a resource would be very valuable to the genetic community, I have several technical comments/concerns and suggestions on the analyses which I think need to be addressed for the results to be sound and more broadly applicable.

Major comments:

1\. The authors performed QTL (association) analysis between SNPs found in polyadenylation signals (PAS) within 40 nucleotides of annotated 3' UTR polyadenylation (p(A)) sites and p(A) site usage based on reads that map to the common 3' UTR segment (upstream of the pA site) relative to the reads that map to the alternative 3' UTR segment (downstream of the pA site). While this is a first obvious region to inspect for genetic effects on polyadenylation, as disruption of the canonical PAS has been shown to have strong effect on pA usage, there may be other cis effects on polyadenylation (e.g., binding of RNA-binding protein to the DNA). I think it would be informative to test for genetic associations with pA usage considering also variants further away from the 3' UTR, e.g., within +/-1Mb of the pA site (this would identify other types of mechanisms that may affect pA usage).

2\. Also, in computing pA site usage, did the authors apply a lower bound cutoff of number of reads that map to the 3' UTR or lower bound density of reads per Kb?

3\. If a PAS SNP had more than one annotated p(A) site within downstream 40 nucleotides, the nearest pA site was taken. Why not test all adjacent pA sites and correct for this in the permutation analysis when assessing significance of associations per gene?

4\. There is no mention of adding hidden expression covariates (e.g., PEER factors, Stegle et al., 2012) to the linear regression model of the pA-QTL analysis. It is very important to add expression covariates, as for example the first expression PEER factors in GTEx are highly correlated with ischemic time that affect RNA degradation, which is a factor that can affect the pA usage, or cellular composition heterogeneity. The PEER factors are provided on the GTEx portal (<https://www.gtexportal.org/home/>) for all tissues.

5\. For the pA-QTL analysis the authors use a minor allele frequency cutoff of \>0.1. At the sample size of over 130 samples there is power to detect associations at a minor allele frequency of 0.05.

6\. Can the authors expand on how they computed q-values from the QTL association p-values? Is this using permutation analysis or fitting a beta distribution? Was the FDR applied at the gene level, e.g. taking the best signal per gene? A description of how to properly account for differences in number of variants tested per gene and local LD can be found in GTEx v6 paper (PMID: 29022597) or on the GTEx portal.

7\. To inspect the connection between the effect of the pA-QTLs and genetic associations with complex human diseases and traits, the authors test for overlap/co-occurrence of signals. However, co-occurrence of QTL and GWAS signals may just be by chance, given the clustering of GWAS signals around genes and their high abundance (PMID: 31043754). Bayesian-based colocalization methods have been developed to test whether two co-occurring association signals are tagging the same causal variant or haplotype, such as eCAVIAR (PMID: 27866706) and ENLOC (PMID: 28278150) which consider local allelic heterogeneity. I would recommend applying such methods to gain higher confidence in the potential causal effect of pA-QTLs on complex human traits as for example done in GTEx release v8 preprint (<https://www.biorxiv.org/content/10.1101/787903v1>).

Also, it would be informative to report the direction of effect of pA-QTLs on disease risk or trait variation for those pA-QTLs that colocalize with GWAS associations? Does lengthening or shortening of the transcript tend to be associated with increased risk of disease?

8\. To test whether the 139 pA-QTLs were also significant eQTLs, the authors tested whether the pA-QTL variants were also significant eQTLs. However, similarly to GWAS associations, pA-QTL and eQTL signals may be overlapping but tagging different causal variants. To further support that the pA-QTL and are also eQTLs, I would also recommend applying colocalization analysis between co-occurring pA-QTLs and eQTLs,

9\. To better estimate sharing of pA-QTLs across tissues, there are multi-tissue methods that account for effect size and standard error across tissues, to increase power in each tissue. The multivariate adaptive shrinkage method, MASH (PMID: 30478440) is one such method that estimates tissue sharing and specificity of genetic associations.

Minor comments:

1\. 139 PAS SNPs were found to be significant pA-QTLs at FDR\<5%. For how many genes? Was only one variant association found to be significant per gene?

Reviewer \#2: This is a nicely carried out work on SNP impacts on APA. This is also a timely piece of work, because several studies are reporting similar findings. One key finding of this work is the relationship between 3'UTR size control and gene expression. I have only a few minor comments:

1\. Have the authors tried a different window for SNP analysis than 40 nt? It would be helpful to readers if they can show SNPs in more upstream or downstream regions.

2\. A sizable fraction of APA-affecting SNPs do not involve canonical signals. The authors need to show some of the samples and discuss them.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: None

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Elkon,

Thank you very much for submitting your Research Article entitled \'Systematic identification of functional SNPs interrupting 3\' UTR polyadenylation signals\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The first reviewer had some additional minor points that need to be addressed, whereas the second reviewer happy that you have fully addressed all his concerns.

We, the editors are convinced that your study is of very high interest to the community and substantially advances the 3\' end processing field. That\'s why we would be happy to publish your manuscript, given that the additional minor issues raised by Reviewer 1 can be addressed.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Andreas Gruber

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors of the manuscript "Systematic identification of functional SNPs interrupting 3' UTR polyadenylation signals" have done a lot of work to the revised version and have carefully addressed all of my comments/concerns. I only have a few remaining minor comments:

1\. To test whether the significant pA-QTL colocalize with GWAS signals, the authors tested 124 complex diseases and traits with available summary statistics. They tested for significant colocalization between PAS pA-QTL with GWAS p-values below 1E-05 (Methods, page 13). Given the multiple hypothesis burden of testing millions of common variants in GWAS, the cutoff P\<5E-08 has been typically used as the genome-wide significant cutoff. I would recommend to distinguish between GWAS loci whose lead variant passes genome-wide significance and those that are subthreshold associations (5E-08\<p\<1e-05), analysis.=\"\" colocalization=\"\" consider=\"\" example=\"\" for=\"\" genome-wide=\"\" gwas=\"\" in=\"\" just=\"\" or=\"\" signals=\"\" significant=\"\" the=\"\" to=\"\"\>

2\. On the top of page 6, the authors point out that they did not capture the known association between the PAS SNP in the 3\'UTR of IRF5 and risk for SLE when setting the eCAVIAR parameter for number of putative causal variants to 1, "because this locus likely contains several causal variants that act through different mechanisms, some of which have a stronger effect on IRF5 expression and SLE risk than the PAS pA-QTL (S4 Fig)." This indeed seems to be the case. The authors go on to test this by setting the parameter to multiple potential causal variants in the SLE GWAS and eQTL loci, and report that then they do find significant colocalization with 3-5 putative causal variants. Can the authors add these results to a supplementary table? What are the posterior probabilities of the lead GWAS and pA-QTL variants?

3\. On the bottom of page 5, in the sentence: "Overall, 512 pA sites were significantly associated (FDR=5%) with a pA-QTL in at least one tissue (see examples in Fig 2B-D; S3 Table)." it should be written FDR\<=5%, not (FDR=5%).

4\. On the bottom of page 6, the authors report the results of testing for colocalization of co-occurring PAS pA-QTLs and eQTLs, also in Table S3: "Of the PAS pA-QTLs that overlapped an eQTL, 51 showed a high colocalization in at least one tissue (S3 Table)." I think it would be helpful to generate a table that summarizes just these 51 significantly colocalizing results, to be able to easily view these results over the thousands of tests performed across all tissues.

5\. On the top of page 7 and in Figure 5C, the authors note that 3\'UTR lengthening in all tissues is significantly associated with decreased expression of the target gene. Is this for all overlapping pA-QTL and eQTL or just for the 51 significantly colocalizing loci? If the latter, it would be clearer to write 'Colocalizing pA-QTL / eQTL loci' in the x-axis of Fig. 5C.

6\. In figures 5D and 7D, arrows that indicate the direction of the link between the PIA and gene expression were added only to a subset of the genes by tissue squares. Were they added only to significantly colocalizing pA-QTL/eQTL loci? If so, I would recommend clarifying this in the figure legends.

7\. On the top of page 6, I would add the words "per tissue" at the end of the following sentence: "Defining per pA site with a significant association a 95% credible set of variants, this analysis implicated the PAS SNP as a causal variant for 55%-70% of the observed pA-QTLs (Fig3A)."

8\. In the Methods section on the bottom of page 12 and on pages 13 and 14, the authors use the term 't-score' to represent the regression slope divided by its standard error. I think it is more correct to call this value 't-statistic'.

9\. There is a typo on the bottom of page 13: 'GETx' should be 'GTEx'.

10\. There is a typo on the top of page 14: -keep alle-order should be '-keep allele-order'.

11\. There is a typo in the word 'slop' (should be 'slope') in the MASH paragraph in the Methods section on the bottom of page 14.

Reviewer \#2: The authors have addressed all my concerns.\</p\<1e-05),\>

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pgen.1008977.r004
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© 2020 Barsh, Gruber
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Barsh, Gruber

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1 Jul 2020

Dear Dr Elkon,

We are pleased to inform you that also reviewer 1 has now accepted your revised work. Thus we are very happy to accept your manuscript entitled \"Systematic identification of functional SNPs interrupting 3\' UTR polyadenylation signals\" for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Andreas Gruber

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have addressed all of my comments satisfactorily. I have no additional comments. The manuscript is ready for publication.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01596R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008977.r006
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10 Aug 2020

PGENETICS-D-19-01596R2

Systematic identification of functional SNPs interrupting 3\'UTR polyadenylation signals

Dear Dr Elkon,

We are pleased to inform you that your manuscript entitled \"Systematic identification of functional SNPs interrupting 3\'UTR polyadenylation signals\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Kaitlin Butler

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom

<plosgenetics@plos.org> \| +44 (0) 1223-442823

[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics

[^1]: The authors have declared that no competing interests exist.
